Leeds spin-out Evocutis aims to remodel its business into either selling or licensing its LabSkin product after disappointing 2013.

Evocutis, a life sciences spin-out of Leeds University, is looking to either sell or license out its LabSkin product after poor performance in 2013.

The decision comes on the back of a stalling in takeover talks in the last quarter of 2013 as the company looked to merge with another firm from the UK, US, or Europe. The company warned at the time that it may go bust without developing new trading relationships.

Evocutis’ primary product, LabSkin, simulates living skin…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?